Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomePreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Change in Accured Expenses (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Change in Accured Expenses for 12 consecutive years, with -$32000.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 100.83% to -$32000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$169000.0 through Dec 2025, changed 0.0% year-over-year, with the annual reading at -$169000.0 for FY2025, 0.0% changed from the prior year.
  • Change in Accured Expenses hit -$32000.0 in Q4 2025 for vTv Therapeutics, up from -$47000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.4 million in Q1 2022 to a low of -$3.4 million in Q2 2024.
  • Historically, Change in Accured Expenses has averaged $209588.2 across 5 years, with a median of -$47000.0 in 2025.
  • Biggest five-year swings in Change in Accured Expenses: soared 841.41% in 2021 and later crashed 2143.41% in 2022.
  • Year by year, Change in Accured Expenses stood at $3.3 million in 2021, then plummeted by 83.21% to $561000.0 in 2022, then skyrocketed by 422.1% to $2.9 million in 2023, then surged by 31.34% to $3.8 million in 2024, then crashed by 100.83% to -$32000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for VTVT at -$32000.0 in Q4 2025, -$47000.0 in Q3 2025, and $746000.0 in Q2 2025.